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Background: In infected lungs of the cystic fibrosis (CF) patients, opportunistic pathogens and mutated cystic fibrosis transmembrane conductance
regulator protein (CFTR) contribute to chronic airway inflammation that is characterized by neutrophil/macrophage infiltration, cytokine release
and ceramide accumulation. We sought to investigate CF lung inflammation in the alveoli.
Methods: Lung tissue from 14 CF patients and four healthy individuals was analyzed for numbers of effector cells, elastin and collagen
concentrations, inflammatory markers and density of Pseudomonas aeruginosa. Additionally, desmosine and isodesmosine concentrations were
determined in 52 urine specimens from CF patients to estimate the burden of elastase activities in respiratory secretions.
Results: Elastin concentration was significantly decreased and collagen significantly increased in CF alveolar tissues as compared to age-matched,
healthy individuals. Elastin split products were significantly increased in urine samples from patients with CF and correlated inversely with age,
indicating local tissue remodelling due to elastin degradation by unopposed proteolytic enzymes. Alveolar inflammation was also characterized by
a significant cell infiltration of neutrophils, macrophages and T cells, extensive nuclear factor-κB and insulin-like growth factor-1 activation in
various cell types and increased intercellular adhesion molecule-1 expression, and increased numbers of myofibroblasts. Additionally, ceramide
accumulated in type II alveolar epithelial cells, lacking CFTR. P. aeruginosa organisms were rarely present in inflamed alveoli.
Conclusions: Chronic inflammation and remodeling is present in alveolar tissues of the CF lung and needs to be addressed by anti-inflammatory
therapies.
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Functional deficiency of the CF transmembrane conductance
regulator (CFTR) leads to airway surface liquid depletion due to
abnormal ion flux and impaired mucociliary clearance in the CF
lung [1–3]. Poor mucociliary clearance is thought to favor lung
infection with opportunistic bacterial pathogens such as
Staphylococcus aureus and Pseudomonas aeruginosa [4,5],
which leads to a pronounced influx of neutrophils into the
airways [6].
Neutrophil-dominated airway inflammation has been implicat-
ed as a key feature of airway remodeling and bronchiectasis. This
process is mediated by the production of reactive oxygen species
and serine and metallo-proteases, which are associated with lung
fibrosis [7]. Bronchial wall thickening, bronchiectasis and lung
tissue fibrosis have been demonstrated in CF patients [8–11].
Although bronchial inflammation has been extensively studied
[4,12,13], little is known about inflammation in the alveolar
space of CF patients. A study of clinical findings and lung pa-
thology in lungs explanted from children concluded that inflam-
mation is centered in the airways, rather than the alveoli, and that
bronchial inflammation and damagewas the real “Achilles heel” of
CF lung disease and that airway obstruction, chronic endobron-
chial infection and inflammation interact continually and eventu-
ally culminate in lung destruction [14]. This picture of CF lung
pathology might suggest that the periphery of the lung is less
affected in the chronic disease process.
We questioned this notion using qualitative and quantitative
immunofluorescence and immunohistology methods to assess
the presence of innate immune cells, particularly neutrophils,
alveolar macrophages and CD3-positive T cells, and myofibro-
blasts in the alveolar tissue of CF patients post lung transplan-
tation. Additionally we sought to know whether the pro-
inflammatory molecules nuclear factor-κB (NF-κB), insulin-
like growth factor-1 (IGF-1) and intercellular adhesion molecule-
1 (ICAM-1) are expressed in the periphery of the CF lungs.
Furthermore, we addressed the issue of tissue remodelling in CF
alveoli with regard to elastin cleavage and collagen substitution.
Finally, we pursued the notion that alveolar inflammation might
be linked to CFTR dysfunction [15–19], particularly to the
sphingolipid metabolism [18]. We therefore investigated the
expression of the pro-inflammatory molecule ceramide in
alveolar type II cells which express CFTR in healthy individuals
[20–23]. Herewe present evidence of extensive inflammation and
tissue remodeling in end-stage CF lungs which warrants anti-
inflammatory treatment strategies for CF patients.
2. Methods
2.1. Patients
Explanted lung tissue was obtained from 14 CF patients who
were chronically infected with P. aeruginosa prior to undergoing
lung transplantation (mean age±SD: 28±8 yrs, range: 13–
38 yrs) (CF Centre of the University of North Carolina, Chapel
Hill, USA, University of Southern California, Los Angeles, USA,
Department of International Health, Immunology and Microbi-ology, University of Copenhagen, Copenhagen, Denmark). Lung
tissues from the contralateral donor lung of four otherwise healthy
individuals (mean age: 26±8 yrs; range: 18–32 yrs) were
investigated as controls (University of Southern California, Los
Angeles, USA). The genotypes of 4/14 CF patients were
available. Three patients were ΔF508 homozygous and one
patient was ΔF508 heterozygous carrying the 1303K/W128X
mutation. Study protocols were approved by the respective local
Human Subjects Committees.
2.2. Immunohistochemical staining procedures
Tissue blocks of∼10×10×10 mmwere cut and stored at 4 °C
in DMEM/HAM's F12 medium (mixed 1:1) (Gibco, Eggenstein,
Germany), supplemented with nystatin (10,000 units/ml, Gibco)
and penicillin/streptomycin (50 µg/ml, Gibco). Blocks were
washed in phosphate-buffered saline (PBS), pH 7.4, fixed in
freshly prepared 4% or 10% formaldehyde (Sigma, Steinheim,
Germany), embedded in paraffin or were shock frozen in liquid
nitrogen. Blocks were cut in 5 µm thin sections (Microtome Jung
HN 40, Leica, Frankfurt, Germany) and transferred to glycerin-
coated slides (Langenbrinck, Emmendingen, Germany). Prior to
the stainings, sections were de-paraffinized using xylol (Merck,
Darmstadt, Germany) and decreasing (100% to 70%) alcohol
concentrations. Overall three to five blocks of alveolar lung tissue
from different parts of the lung periphery of 14 CF patients and 4
healthy individuals were used for this study. From each lung
tissue block every 6th or 10th section was stained. Consequently
90 to 150 sections of each CF patient and healthy individual were
analyzed.
For immunohistochemical staining the Alkaline Phosphatase
(AP) or Horseradish Peroxidase (HRP) system (Dako, Ham-
burg, Germany) was used. Tissue sections were incubated for
30 min with swine or goat serum, diluted 1:10 in PBS/Tween 20
(Sigma) to block non-specific binding of rabbit IgG antibodies
directed against human elastin, collagen type I (Biotrend, Köln,
Germany), human insulin-like growth factor I (hIGF-1,
Mediagnost, Reutlingen, Germany), P. aeruginosa alginate
and to block non-specific binding of monoclonal antibodies
directed against human neutrophil elastase, CD3 and against
alveolar macrophage CD68 receptors (Dako, diluted 1:100).
After incubation with the appropriate second antibody and
washing, sections were embedded in Faramount aqueous
mounting medium (Dako). Controls for non-specific staining
were performed without adding the first antibody.
For NF-κB and ICAM-1 staining, paraffin sections were
incubated with Proteinase K for 10 min at 37 °C. After repeated
washings the sections were incubated with Methanol-H2O2 for
10 min at room temperature and washed three times. The
sections were then incubated with swine serum (dilution 1:10)
for 30 min and after with the monoclonal antibody against NF-
κB (diluted 1:50; BD Bioscience Pharmingen, Heidelberg,
Germany) or the monoclonal antibody against ICAM1 (diluted
1:10; BD Bioscience Pharmingen, Heidelberg, Germany) for
1 h at room temperature. After washing the sections were
incubated with the second antibody (goat anti mouse IgG, HRP
conjugated; diluted 1:100) for 1 h. The sections were washed
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peroxidase substrate.
For quantitative determination of neutrophil and AM
numbers, and elastin and collagen concentrations of alveolar
tissue from CF patients and from control lungs, 10 to 20 digi-
talized images from every section were taken (magnification:
200; area: 400×600 µm). Images containing blood vessels or
erythrocyte-filled alveoli were excluded. The number of
neutrophils and CD3 positive cells were determined per mm
of septum length and the content of elastin and collagen fibers
were determined in percent per mm of septum length.
Macrophages located in alveolar septa and in alveolar lumina
were counted and expressed as macrophages/mm2 lung tissue.
Between 73,000 µm and 173,000 µm of septa/patient and more
than 1000 alveoli of CF patients and controls were studied.
For the presence of P. aeruginosa, 1000 digitalized images
were taken from sections of peripheral lung tissue from CF
patients (magnification: 1000). Sections were analysed with an
Axioplan microscope (Zeiss, Oberkochen, Germany) using
Axiovision (Zeiss).
For immunofluorescence staining frozen sections of alveolar
tissue fromCF patients, and healthy individuals were blockedwith
goat serum (diluted 1:10, Dako) and double stained with a
polyclonal antibody against surfactant protein C (diluted 1:500,
Natu TecGmbH, Frankfurt, Germany) for 1 h at room temperature
and a monoclonal antibody against CFTR (diluted 1:200, Mayo
Clinic, Scottsdale, Arizona, USA) over night at 4 °C or a
monoclonal antibody against ceramide clone MID 15B4, diluted
1:50, Alexis, Grünberg, Germany) for 1 h at room temperature.
Antibody binding was detected with Cy™2-conjugated goat anti
mouse (diluted 1:100, Dianova, Hamburg, Germany) and Cy™3-
conjugated goat anti rabbit (diluted 1:800, Dianova). DNA was
stained with DAPI (5 µg/ml, Sigma). Sections were visualized
using a Axioplan microscope (Zeiss, Oberkochen, Germany) or a
confocal microscope (Zeiss). Ceramide expression was quantita-
tively assessed in a blinded fashion and using the MetaMorph
software (Visitron Systems GmbH, Puchheim, Germany).
2.3. Determination of elastin split products in CF urine specimens
To address the question whether matrix remodeling is present
in lungs of CF patients with younger ages, we also quantified
elastin split products in patient's urines. Urine specimens were
obtained from 52 CF patients (mean age±SD: 22±11 yrs, range:
6–51 yrs), attending different CF centers (Department of
Medicine, University of Wisconsin, Madison, USA; Children's
Hospitals, University of Essen, and University of Düsseldorf,Fig. 1. Increased numbers of neutrophils, alveolarmacrophages andT lymphocytes
are present in alveoli of CF patients. Neutrophils (A, arrow), stained with
monoclonal antibodies directed against human neutrophil elastase, in CF alveolar
lung tissue and in normal alveolar lung tissue differ significantly (pb0.0001) in
numbers. Alveolar macrophages (B, arrow), stained with monoclonal antibodies
directed against CD68 receptors, in CF alveolar lung tissue and in normal alveolar
lung tissue differ significantly (pb0.0001). T lymphocytes (C, arrow), stainedwith
monoclonal antibodies directed against CD3, in CF alveolar lung tissue and in
normal alveolar lung tissue differ significantly (pb0.0001) in numbers.
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patients or their parents. Study protocols were approved by the
respective local Human Subjects Committees. Desmosine (DES)
and isodesmosine (IDES) concentrations were measured in mid-
stream urine samples (200 µl total volume), and neutrophil
elastase activity was determined in supernatant fluids of
expectorated sputum specimens from CF patients using micellar
electrokinetic chromatography [24]. DES and IDES values are
expressed as µg/g creatinine, and MeO-Suc-Ala-Ala-Pro-Val-p-Fig. 2. Inflammatory mediators and transcription factor expression in CF versus norm
alveolar tissue of a CF patient (A, C) and a healthy individual (B, D). In the CF pa
vessels (A, arrow) and alveolar septae (C, arrow), whereas blood vessels (B) and alveo
detection of NF-κB in the alveolar tissue of a CF patient. All alveolar macrophages i
were positive for NF-κB staining in the nuclei (dark brown spots, arrow). These
magnifications: D-J: ×200.nitroanilide was used as substrate for neutrophil elastase. One unit
of neutrophil elastase was defined as the conversion of 1 µmol p-
nitroanilide/min.
2.4. Electron microscopy
For transmission electron microscopy, formalin fixed tissue
blocks of peripheral lung tissue from a CF patient and a healthy
individual were post-fixed with 2.5% glutaraldehyde (Agaral alveolar lung tissue. Immunohistochemical detection of ICAM-1 expression in
tient, positively stained (dark brown) ICAM-1 expression was present in blood
lar septae (D) of a healthy individual were negative. E, G: Immunohistochemical
n alveolar lumina (E) and many cells in the alveolar epithelium (G) of CF lungs
cells were negative for nuclear NFκB in a healthy control (F, H). Original
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tetroxide (Simec, Zofingen, Switzerland) and 0.5% uranyl acetate
(Fluka Chemie GmbH, Sigma-Aldrich, Buchs, Switzerland),
dehydrated in a graded series of ethanol and embedded in epon
(Fluka), according to standard procedures. Ultrathin (60–80 nm)Fig. 3. IGF-1 and myofibroblast expression in CF versus normal alveolar lung tissue. I
between CF alveolar (A, C) and normal alveolar lung tissue (B, D). Myofibroblasts,
normal alveolar lung tissue (F, H) differed largely in expression. Original magnificasections were cut from the tissue blocks, transferred to uncoated
200-mesh copper grids, stained with uranyl acetate and lead
citrate (Ultrostain, Leica, Glattbrugg, Switzerland), and examined
in a Philips 300 transmission electron microscope (Philips AG,
Zürich, Switzerland), operating at 60 kV.GF-1, stained with a polyclonal antibody (red), differed significantly (pb0.0001)
stained with an antibody (dark brown) in CF alveolar lung tissue (E, G) and in
tions: A, B, F, H ×400; C, D, E, G ×200.
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For statistical analysis, raw data were checked for normality
using the Shapiro–Wilks-test. Thereafter, significance was cal-
culated using the Student's t-test or the Wilcoxon test. P-values
of 0.05 or less were considered significant. The Pearson corre-
lation coefficient r was calculated using the Winstat software
(Microsoft, Redmont, Wash., U.S.A.). Results are given as
means±SD.
3. Results
3.1. Inflammatory cells and mediators are greatly increased in
alveoli of CF patients
To assess whether innate and adaptive immune cells are
present in increased numbers in the periphery of the CF lung,
we stained neutrophils, alveolar macrophages and CD3 positive
T cells with specific cell markers and determined the cell
numbers quantitatively after immunostaining. Neutrophil
numbers per mm septum were significantly higher in CF
patients compared to controls (Fig. 1A). Neutrophils were
exclusively located within alveolar septa in CF and healthy lung
tissues. Also the percentages of alveolar macrophage in septae
and intraluminally were greatly increased in CF patients
compared to controls (Fig. 1B). In CF alveoli, the distribution
of both cell types was inhomogeneous: areas with greatly
increased cell counts were interspersed with areas with low cell
numbers. In addition, CD3-positive T lymphocyte cell numbers
were significantly higher in CF alveolar tissues compared to
control tissues (Fig. 1C).
Concentrations of pro-inflammatory cytokines were in-
creased in parallel fashion with innate and adaptive immune
cell numbers in alveolar tissues and in the lumen of alveoli of
CF patients. Increased expression of the cell surface protein
ICAM-1 (Fig. 2A–D) was demonstrated in CF tissues
compared to non-CF control lung tissue. In contrast to lung
tissues from healthy individuals, many cells in alveolar septa,
presumably macrophages in the lumen of alveoli of CF patients
showed nuclear translocation of the transcription factor NF-κB
(Fig. 2E–H).
Because activated epithelial cells and macrophages may
produce various mediators of inflammation, we stained alveolar
tissues of CF patients and controls for the pro-fibrotic growth
factor IGF-1. In contrast to lung tissues from healthy individuals,Fig. 4. Increased elastin degradation and collagen substitution in alveolar septa and in
rabbit IgG antibody directed against human α-elastin, in CF alveolar lung tissue
concentration (B). In CF patients mean elastin values±SD were 9.6±1.5% elastin/m
septum (range: 50.3–55.1% elastin/mm septum) in healthy control lungs. Urinary co
(IDES ♦), determined by micellar electrokinetic chromatography, decrease with age i
DES and IDES concentrations correlate with human neutrophil elastase (HLE) levels
antibody directed against human collagen type 1, in CF alveolar lung tissue (H) and in
(G). Mean collagen type 1 expression±SD in alveolar septa of CF patients was 49.9±
2.6% collagen/mm septum, range: 4.0–9.6% collagen/mm septum) in tissues of health
(I) and increased deposition of collagen in alveolar septae of a CF patient (J). Arrows
F, H ×100; I, J ×3.190.many epithelial cells and macrophages of CF patients stained
positive for IGF-1 (Fig. 3A–D). Furthermore, increased numbers
of myofibroblasts were detectable in CF, but not in control tissues
(Fig. 3E–H).
3.2. Expression of elastin and collagen in CF alveolar septae
and elastin split products in CF urine
Based on the findings of increased neutrophil/alveolar macro-
phage numbers of CF alveoli, as well as the increased concen-
trations of the profibrotic mediator IGF-1 and the collagen
producing myofibroblasts, we addressed the question whether
matrix remodeling is present in CF alveoli by quantifyingα-elastin
in alveolar septa and elastin split products in patient's urine
specimens. Elastin was significantly reduced in CF alveoli as
compared to healthy control lungs (Fig. 4A–C). Corroborating the
extensive loss of elastin, significantly increased desmosine (DES)
(23.5±6.1 µg/g creatinine) and isodesmosine (IDES) (20.6±
5.5 µg/g creatinine) levels were present in urines of CF patients
of all ages as compared to levels of 12 healthy controls (DES:
9.31±2.75 µg/g creatinine, pb0.0001; IDES: 7.34±1.95 µg/g
creatinine, pb0.0001), published previously [24]. The data reflect
ongoing degradation of elastin. When the DES and IDES values
in single patients were compared to each other, both markers of
elastin degradation were highly correlated (r=0.977; pb0.0001).
Additionally, DES and IDES values were inversely correlated to
age of the CF patients (DES r=−0.500, pb0.0001; IDES r=
−0.550, pb0.0001) (Fig. 4D). Because DES and IDES values in
CF urines correlated with human neutrophil elastase levels in
sputum samples of CF patients (DES: r=0.491, p=0.004; IDES:
r=0.555, p=0.001) (Fig. 4E), this serine proteinase likely
contributes to elastin cleavage in CF airways.
The extensive loss of elastin led us to hypothesize that elastin
may be substituted by collagen in alveolar septae of CF patients.
Indeed, staining with a specific antibody for collagen type 1
revealed that its concentration was significantly higher in
alveolar septae of CF patients versus tissues from healthy
controls (Fig. 4F–H). These finding support the hypothesis that
alveolar matrix remodeling and fibrosis is present in the CF lung
and leads to stiffening of alveolar tissues. Elastin was ∼5-fold
decreased and collagen ∼9-fold increased in CF patients versus
healthy controls. When lung tissue from a CF patient and from a
healthy individual was investigated by electron microscopy
(Fig. 4I, J), thickened septae with extensive collagen deposition
were visible in CF but not in age-matched normal lung tissue.creased elastin degradation in urines of CF patients. Elastin fibers, stained with a
(C) and in normal alveolar lung tissue (A) differ significantly (pb0.0001) in
m septum (range: 7.6–12.6% elastin/mm septum), and 52.5±2.3% elastin/mm
ncentrations of the elastin split product desmosine (DES □) and isodesmosine
n 52 CF patients (D). Both markers of elastin degradation were highly correlated.
in sputum samples of CF patients (E). Collagen fibers, stained with a rabbit IgG
normal alveolar lung tissue (F) differ significantly (pb0.0001) in concentration
13.2% collagen/mm septum (range: 30.2–74.6% collagen/mm septum) and 7.3±
y controls. Normal collagen deposition in alveolar septae of a healthy individual
: Insert. Original magnifications: A, C, G, I ×100; Original magnifications: A, C,
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accumulate ceramide
We tested the hypothesis that inflammation in the alveolar
space of CF patients may occur as a consequence of the accu-mulation of the pro-inflammatory sphingolipid ceramide [18].
Since CFTR has been detected in alveolar type II cells [19–23]
of normal human airways, we focused on this cell type.
Immunostaining of alveolar type II cells with antibodies specific
for CFTR (Fig. 5A, D) and surfactant C (Fig. 5B), demonstrated
Fig. 5. Ceramide accumulates in type II alveolar epithelial cells of CF patients. Immunostaining of alveolar type II cells from healthy individuals with a monoclonal
antibody specific for CFTR (A) and a rabbit antibody against surfactant C (B); C: overlay of A and B. D, E: Confocal microscopy of alveolar type II cells from a
healthy individual (D) and a ΔF508 homozygous CF patient. (E) with a monoclonal antibody specific for CFTR. Immunostaining of alveolar type II cells from CF
patients (F, G) and healthy individuals (I, J) with a monoclonal antibody specific for ceramide (F, I) and a rabbit antibody against surfactant C (G, J). H: overlay of F, G,
K: overlay of I, J. Original magnifications: A–C, F–K: ×200; D, E ×400.
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individuals (Fig. 5C). In contrast, CFTR staining of alveolar
type II cells was absent in lung tissues from ΔF508
homozygous CF patients (Fig. 5E). Staining of peripheral
lung tissue from CF patients and control tissues from healthyindividuals with an antibody specific for ceramide revealed
ceramide accumulation in alveolar cells of CF patients (Fig. 5F),
but not in the corresponding cells from healthy individuals
(Fig. 5I). Using the MetaMorph software ceramide accumula-
tion was significantly higher in cells from CF patients (mean
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cells of healthy individuals (mean fluorescence intensity±SD:
49.5±5.9) (p=0.001). Double staining of the tissues with an
antibody specific for ceramide and surfactant C identified these
cells as type II alveolar epithelial cells (Fig. 5G, H). These
findings show that CF alveolar type II cells accumulate
ceramide.
3.4. P. aeruginosa in alveoli of CF patients
P. aeruginosa is a potent stimulant of various pathways of
inflammation including stimulation of acid sphingomyelinase
resulting in ceramide accumulation [25]. To address the
question whether P. aeruginosa cells would reach the alveoli
from sites of endobronchial infection, we stained alveolar
tissues from nine CF patients with chronic P. aeruginosa
infection with an antibody specific for alginate. Only 74 P.
aeruginosa cells were detected in eight alveolar tissue sections
of three CF patients, indicating a relative paucity of bacteria in
alveolar spaces.
4. Discussion
While inflammation and tissue damage within conductive
airways has been well-demonstrated and repeatedly reported,
surprisingly little is known about alterations at the cell and
tissue level in the peripheral lung in CF patients [8–12]. Our
study provides evidence for extensive tissue inflammation and
remodeling in the alveolar space of CF patients with advanced
lung disease. Our findings are supported by (i) the detection of
increased numbers of neutrophils, macrophages and T cells lo-
cated in alveolar septa, (ii) an up-regulation of ICAM-1 in these
tissues, (iii) the activation of NF-κB and IGF-1 in macrophages
and alveolar epithelial cells, (iv) an increased presence of
collagen-producing myofibroblasts, and (vi) extensive elastin
degradation and collagen substitution in alveolar tissues. Addi-
tionally, and in line with the notion that airway inflammation is
detectable very early in the lives of CF patients [26–28], our
data indicate that lung elastin degradation is not limited to end
stage disease. This notion is evidenced by the determination of
the crosslink amino acids DES and IDES using the validated
MEKC technique [24] in urine specimens from CF patients with
different ages including younger patients with milder lung
disease. Our data confirm those of previous investigators [29],
who using an isotope dilution method found similar levels of
increased urinary DES and IDES in CF patients. In contrast to
their study, we were able to correlate urinary DES and IDES
levels with levels of active neutrophil elastase in CF sputa.
While urinary DES and IDES are not tissue specific, the
correlation with neutrophil elastase which is abundantly present
in inflamed and infected CF airways [29,30], strongly suggests
that the site of excess elastin degradation in patients with CF is
the lung. Also in COPD patients, urinary DES levels have been
inversely correlated with the severity of lung disease, suggest-
ing an irreversible loss of lung elastin [31].
Both neutrophils and macrophages, located in high numbers
within the alveolar septae contain proteases that can be releasedand cleave structural proteins such as lung elastin [7,32,33], and
increased numbers of these cells have been detected in CF
bronchoalveolar lavage (BAL) fluids, including BAL fluids from
very young children with CF [12,34–38]. In the light of the
findings of Hilliard and colleagues who reported that elastase
activity and matrix metalloproteinase-9 (MMP-9) concentrations
correlated with increased concentrations of collagen, glycosami-
noglycans and elastin in BAL fluids of CF patients [38], the
mechanisms of airway remodelling in childrenwithCFmay differ
regionally between central and peripheral areas. A reasonable
explanation for the observed alveolar tissue inflammation and
remodeling in CF lungs is that single bacterial cells from the large
burden of bacterial pathogens causing chronic endobronchial
infection in the conductive airways enter the 5 µm opening of the
alveoli, thereby triggering and sustaining inflammation in
alveolar spaces. However, we could only detect a surprisingly
small number of P. aeruginosa cells in CF alveoli. P. aeruginosa
was present in only three of 9 CF patients chronically infected
with this pathogen within the alveolar lung tissue. Additionally,
only 74 P. aeruginosa cells were detected in tissue from the 3
patients with bacteria in their alveoli. This finding may be a
consequence of the high number of professional phagocytes in CF
alveoli that may rapidly phagocytose and kill the invading
bacteria. However, neutrophils, present only in alveolar septa, did
not reveal the presence of internalized P. aeruginosa when
alveolar tissues were investigated with a P. aeruginosa-specific
antibody. Additionally, none of the luminal or intraseptal alveolar
macrophages which have been reported to have an impaired
killing activity towards P. aeruginosa due to defective acidifica-
tion in phagolysosomes [39], revealed the presence of internalized
P. aeruginosa. Alternatively, alveoli may be kept sterile by the
intense antibiotic regimen which all of the patients received, and
planktonic P. aeruginosamay be readily cleared in distal alveolar
tissues as reported previously [40], in contrast to more proximal
airways where they tend to form alginate-protected colonies that
are resistant to immune cell attack and penetration by antibiotics.
The large number of P. aeruginosa-free alveoli that,
nonetheless, reveal extensive fibrosis may support the hypoth-
esis that pulmonary inflammation in CF patients is triggered by
endogenous factors. This hypothesis is supported by reports
demonstrating that lung inflammation is detectable in some CF
patients who lack evidence of ongoing bacterial infection [26–
28] and that uninfected CF airway grafts, but not grafts from
matched non-CF controls, undergo a time-dependent, neutro-
phil-mediated inflammation that leads to progressive lung tissue
destruction when these grafts are placed in severe combined
immunodeficiency mice [41]. Furthermore, our previous data
reveal that CFTR-mediated ceramide accumulation triggered an
increased synthesis and release of cytokines and a profound
recruitment of neutrophils and macrophages in bronchial tissues
of uninfected CF mice in contrast to control mice [18].
However, the “intrinsic hyper-inflammation” hypothesis is
still controversely discussed, since conflicting results, ranging
from increased NF-κB activation and production of IL-8 to no
changes or even decreased levels of inflammatory cytokines
have been reported in investigations using nasal or bronchial
epithelial cells from CF or non-CF individuals or immortalized
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[42,43]. Our study does not add significant information about
the aetiology of alveolar-based inflammation in CF. This is
basically a consequence of the major difficulty to obtain
sequential lung tissues or lung tissues at all from CF patients
without lung infection. Because CF mice are strikingly different
compared to CF patients concerning pulmonary pathophysiol-
ogy [44], they may not represent a particularly good model to
study alveolar-based inflammation in CF. Samples from non-
CF bronchiectasis patients undergoing heart-lung transplant
may be valuable to shed more light on the infection-
inflammation question. Our data reveal that ceramide accumu-
lation is also present in alveolar epithelial cells of CF patients.
Whether ceramide accumulation is a consequence of defective
CFTR, as demonstrated previously in uninfected mice [18], or
triggered by bacteria [25] or other inflammatory stimuli, as
observed in patients with COPD [45], is difficult to decide when
examining lung tissue retrieved from chronically infected CF
patients. However, our finding that ceramide accumulation is
restricted to alveolar type II cells of CF patients discriminates
CF from COPD, where ceramide accumulation has also been
observed in type I alveolar cells [45].
Our observation that large numbers of macrophages and
epithelial cells reveal nuclear translocation of NF-κB further
supports our notion of alveolar inflammation in CF lungs. Several
factors including ceramide [46,47], tumor necrosis factor(TNF)-α
[48] and bacterial factors [49] activate this transcription factor. In
CF knockout (KO) mice, challenged intratracheally with P.
aeruginosa, a prolonged and excessive activation of NF-κB, high
concentrations of pro-inflammatory cytokines and higher neutro-
phil numbers were detected in BAL fluids compared to wild type
mice, suggesting that dysregulation of the IκB/NF-κB pathway in
the CF lung leads to prolonged cytokine secretion and persistent
inflammation in response to acute challenges [49]. Up-regulated
NF-kB has also been detected in cultures of CF airway epithelial
cells [15–17]. Nevertheless, conflicting results have been
published concerning this topic [42,43]. Thus, again both
exogenous and endogenous factors may be responsible for the
increased NF-κB activation in CF alveolar tissues.
Another important mediator of fibrosis, which we detected in
high concentrations in macrophages and alveolar epithelial cells
of CF patients, is IGF-1. IGF-1 stimulates proliferation of fibro-
blasts, presumably by inhibition of apoptosis, and is also a potent
inducer of collagen synthesis [50,51]. Increased IGF-1 mRNA
has been detected in lung tissues following the induction of
bleomycin-induced pulmonary fibrosis in mice [52]. Additional-
ly, other growth factors including transforming growth factor-ß
(TGF-ß) have been detected in inflamed CF airways [12].
In summary, we have demonstrated extensive inflammation
and tissue remodeling in alveolar tissues from CF patients with
advanced lung disease, and these changes are likely to occur and
progress despite antibacterial therapies and need to be countered
via other therapeutic strategies that target inflammation and
fibrosis. Bronchial inflammation has been the main target of anti-
inflammatory therapeutic regimens. Such strategies, which consist
of primarily of delivering anti-inflammatory drugs including cor-
ticosteroids [53,54] and protease inhibitors [55,56] via inhalation,may have a therapeutic impact on bronchial inflammation, but
they may not necessarily down-regulate alveolar inflammation,
especially in patients with more advanced disease where depo-
sition of inhaled agents in the lung periphery is limited and shows
marked regional heterogeneity because of bronchial obstruction.
Future studies should focus on whether suppurative non-CF lung
disease exhibits similar or different abnormalities.Acknowledgements
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